............................
2015
2014
2013
Archive
............................
Portfolio News
............................
New Leaf News
............................
|
Durata Therapeutics Prices Initial
Public Offering
MORRISTOWN, N.J.--July 19, 2012--Durata Therapeutics today announced the
pricing of its initial public offering of 7,500,000 shares of common
stock at a public offering price of $9.00 per share, before underwriting
discounts. The shares are scheduled to begin trading on the NASDAQ
Global Market on July 19, 2012 under the ticker symbol "DRTX."
In addition, the underwriters have an option for a period of 30 days to
purchase up to an additional 1,125,000 shares of common stock from
Durata at the public offering price, less the underwriting discount. The
offering is expected to close on or about July 24, 2012.
BofA Merrill Lynch and Credit Suisse Securities (USA) LLC are acting as
joint book-running managers for the offering. RBC Capital Markets, LLC
and Wedbush PacGrow Life Sciences are acting as the co-managers for the
offering.
A registration statement relating to these securities was declared
effective by the Securities and Exchange Commission on July 18, 2012.
The offering is being made only by means of a prospectus, copies of
which may be obtained from BofA Merrill Lynch, 222 Broadway, 7th Floor,
New York, NY 10038, Attn: Prospectus Department, or via email, at
dg.prospectus_requests@baml.com or Credit Suisse Securities (USA) LLC,
Attn: Prospectus Department, One Madison Avenue, New York, NY 10010,
telephone 800-221-1037, or via email, at
newyork.prospectus@credit-suisse.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of, these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of such state or jurisdiction.
About Durata Therapeutics
Durata Therapeutics is a pharmaceutical company focused on the
development and commercialization of novel therapeutics for patients
with infectious diseases and acute illnesses. Durata is currently
enrolling and dosing patients in two global Phase 3 clinical trials with
its lead product candidate, dalbavancin, for the treatment of patients
with acute bacterial skin and skin structure infections, or abSSSI. |